title: Sulfasalazine in rheumatoid arthritis. A double-blind, placebo-controlled  trial.
abstract: Sulfasalazine (SSZ), 3 gm daily, was compared with placebo for treatment of rheumatoid arthritis, in a 15-week randomized, parallel, double-blind trial. Joint tenderness and swelling, morning stiffness, grip strength, and pain score all showed significantly more improvement with SSZ than with placebo. Adverse effects, particularly gastrointestinal reactions, led to withdrawal from the study of 28% of the patients who had been receiving SSZ, but these effects were all readily reversible and not life-threatening. These results confirm previous findings that suppression of rheumatoid synovitis may be induced by SSZ, within 2 months after full maintenance doses are reached.
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D010352:Patient Dropouts; D011930:Reaction Time; D012460:Sulfasalazine / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D012460:Sulfasalazine